In An Organic Compound Patents (Class 424/1.65)
-
Patent number: 8894971Abstract: The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are novel radioiodinated BTMs prepared using the method, as well as radiopharmaceutical compositions comprising such radioiodinated BTMs. The invention also provides radioiodinated intermediates useful in the method, as well as in vivo imaging methods using the radioiodinated BTMs.Type: GrantFiled: December 10, 2010Date of Patent: November 25, 2014Assignee: GE Healthcare LimitedInventor: Michelle Avory
-
Patent number: 8894970Abstract: The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.Type: GrantFiled: July 26, 2011Date of Patent: November 25, 2014Assignee: Corridor Pharmaceuticals, Inc.Inventors: Bruce Edward Tomczuk, Gary Lee Olson, Richard Scott Pottorf, Lijuan Jane Wang, Bhaskara Rao Nallaganchu, Yanqun Zhang
-
Patent number: 8894976Abstract: The invention relates to a family of dyes which fluoresce in the UV-VIS, far red and near infrared wavelengths of the spectrum and possess asymmetric lipophilic alkyl chains. The dyes of the invention are soluble in commercially available membrane staining dyes, are useful as probes for rapidly staining lipophilic structures such as membranes in cells or isolated from cells, and are well-retained therein. Methods of utilizing the dyes to detect stained cells both in vivo and in vitro are also disclosed.Type: GrantFiled: November 17, 2006Date of Patent: November 25, 2014Assignee: Phanos Technologies, Inc.Inventor: Brian D. Gray
-
Publication number: 20140341805Abstract: A method of imaging a region in a subject includes administering to the subject a complex of a metal chelated to a compound, and obtaining an image of the region in the subject.Type: ApplicationFiled: July 29, 2014Publication date: November 20, 2014Applicant: MOLECULAR INSIGHT PHARMACEUTICALS, INC.Inventors: John W. BABICH, Craig ZIMMERMAN, John JOYAL, Kevin P. MARESCA, John MARQUIS, Genliang LU, Jian-cheng WANG, Shawn HILLIER
-
Publication number: 20140341804Abstract: The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (?-, ?-)dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.Type: ApplicationFiled: November 30, 2012Publication date: November 20, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Martin Gilbert Pomper, Sangeeta Ray, Ronnie C. Mease
-
Publication number: 20140341995Abstract: Described is a conjugate of agent complex and at least one target-finding ligand, where the agent complex comprises an agent encapsulated by an encapsulation material and where the target-finding ligand is a prostacyclin analog, and the use of the conjugate.Type: ApplicationFiled: March 24, 2014Publication date: November 20, 2014Applicant: ETHRIS GMBHInventors: Carsten Rudolph, Johannes-Peter Geiger
-
Publication number: 20140341806Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.Type: ApplicationFiled: August 5, 2014Publication date: November 20, 2014Inventors: Jeffrey P. Norenberg, Richard S. Larson
-
Patent number: 8889839Abstract: This invention relates to novel Ln(III) complexes of pybox, and methods of making the same. The present invention also relates to a method of use of pybox as a chelating moiety and sensitizer for Ln(III) ion luminescence. Derivatives of pybox and methods of making the same are also provided.Type: GrantFiled: May 7, 2008Date of Patent: November 18, 2014Assignee: Syracuse UniversityInventors: Ana de Bettencourt-Dias, Subha Viswanathan
-
Patent number: 8889100Abstract: The present application discloses compositions and methods of synthesis and use of 18F- or 19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may then be directly or indirectly attached to the targeting molecule. In other embodiments, the 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the bifunctional chelating agent bound to 18F- or 19F-metal complex may be conjugated to the molecule to be labeled at a reduced temperature, e.g. room temperature.Type: GrantFiled: March 6, 2014Date of Patent: November 18, 2014Assignee: Immunomedics, Inc.Inventors: Christopher A. D'Souza, William J. McBride, David M. Goldenberg
-
Patent number: 8877970Abstract: Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by over expression of CA-IX comprise a complex that contains a sulfonamide moiety which is capable of binding the active catalytic site of CA-IX, and a radionuclide adapted for radioimaging and/or radiotherapy:Type: GrantFiled: January 8, 2009Date of Patent: November 4, 2014Assignee: Molecular Insight Pharmaceuticals, Inc.Inventors: Craig Zimmerman, John W. Babich, John Joyal, Genliang Lu, Kevin P. Maresca, Chris Barone
-
Patent number: 8877157Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.Type: GrantFiled: July 8, 2010Date of Patent: November 4, 2014Assignee: Lantheus Medical Imaging, Inc.Inventors: Richard R. Cesati, Thomas D. Harris, Simon P. Robinson, Richard J. Looby, Edward H. Cheesman, Padmaja Yalamanchili, David S. Casebier
-
Patent number: 8877159Abstract: The present invention provides methods and uses of phospholipid ether analogs as diagnostic and therapeutic agents for numerous cancers.Type: GrantFiled: August 12, 2013Date of Patent: November 4, 2014Assignee: Cellectar, Inc.Inventors: Jamey P. Weichert, Marc Longino, Anatoly Pinchuk
-
Patent number: 8877160Abstract: The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.Type: GrantFiled: August 12, 2013Date of Patent: November 4, 2014Assignee: Cellectar, Inc.Inventors: Jamey P. Weichert, Marc Longino, Anatoly Pinchuk
-
Patent number: 8865124Abstract: The present invention relates to fluorescent or luminescent probe reagents for measuring oxidative stress in a cell or an organism. Examples of the probe reagents include: a fluorescent or luminescent protein and a marker protein; a fluorescent or luminescent protein, a marker protein, and a regulatory factor; or a fluorescent or luminescent protein, a marker protein, a cleavage sequence, and a regulatory factor. In the probe reagents, the marker protein makes it possible to detect the oxidative stress caused by reactive oxygen species and comprises a regulatory factor-binding site and a ubiquitin-binding site; and the regulatory factor is a protein making it possible to regulate degradation of the marker protein in response to the reactive oxygen species. The present invention also relates to a method of measuring oxidative stress in a cell or an organism, or a method of screening a substance which suppresses or promotes the oxidative stress in a cell or an organism by using the probe reagent.Type: GrantFiled: February 27, 2009Date of Patent: October 21, 2014Assignees: Japan Science and Technology Agency, RikenInventors: Atsushi Miyawaki, Kazuki Sasaki
-
Patent number: 8865125Abstract: The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are novel radioiodinated BTMs prepared using the method, as well as radiopharmaceutical compositions comprising such radioiodinated BTMs. The invention also provides radioiodinated intermediates useful in the method, as well as in vivo imaging methods using.Type: GrantFiled: August 20, 2010Date of Patent: October 21, 2014Assignee: GE Healthcare LimitedInventors: Michelle Avory, William John Trigg
-
Patent number: 8865126Abstract: The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The invention provides a compound of the formula for use in such methods. In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid of the formula H2NCHRCOOH, M is a cation of a radionuclide, n is 1 or 0, K is 1 or 0, and the compound can be in a pharmaceutically acceptable carrier therefor. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.Type: GrantFiled: October 18, 2012Date of Patent: October 21, 2014Assignee: Endocyte, Inc.Inventors: Christopher P. Leamon, Matthew A. Parker
-
Patent number: 8858911Abstract: Tracers targeting phosphodiesterase 1 for use in gamma radiation detection-based diagnostic techniques, particularly gamma-emitter labeled tracers for SPECT and positron emitter-labeled compositions for PET are disclosed. Radio-labeled multiple novel scaffolds as PDE1 inhibitors such as substituted pyrazolo-pyrimidin-4-one derivatives, biomarkers for phosphodiesterase 1 [PDE1) in vivo, methods for developing novel therapies for PDE1-implicated conditions such as pulmonary arterial hypertension (PAH), Central Nervous System (CNS) and Cardiovascular (CV) disorders, and methods of detection and treatment are also disclosed.Type: GrantFiled: October 7, 2010Date of Patent: October 14, 2014Assignee: Intra-Cellular Therapies, Inc.Inventors: Peng Li, Lawrence P. Wennogle, Jun Zhao, Hailin Zheng
-
Patent number: 8852550Abstract: The present invention relates to improved chelator conjugates with biological targeting molecules, suitable for forming metal complexes with radiometals. The radiometal complexes, especially with the radiometal 99mTc, are useful as radiopharmaceuticals.Type: GrantFiled: October 1, 2009Date of Patent: October 7, 2014Assignee: GE Healthcare LimitedInventors: Colin Mill Archer, Harry John Wadsworth, Torgrim Engell
-
Patent number: 8852553Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.Type: GrantFiled: December 21, 2012Date of Patent: October 7, 2014Assignee: Lantheus Medical Imaging, Inc.Inventors: Richard R. Cesati, Thomas D. Harris, Simon P. Robinson, Richard J. Looby, Edward H. Cheesman, Padmaja Yalamanchili, David S. Casebier
-
Patent number: 8846602Abstract: The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance covalently bonds to the body fluid constituents or tissue constituents via the protein-binding molecule, thus providing a form of transport of the active agent that an be hydrolytically or enzymatically cleaved, according to pH, in the body while releasing the active agent.Type: GrantFiled: March 7, 2012Date of Patent: September 30, 2014Assignee: KTB Tumorforschungs GmbHInventor: Felix Kratz
-
Patent number: 8846001Abstract: The present invention provides radioactive gallium complexes which comprise DOTA-biotin conjugates, incorporating a linker group. Also described are radiopharmaceutical compositions, and methods and uses of the complexes for in vivo imaging involving pre-targeting with avidin.Type: GrantFiled: September 16, 2010Date of Patent: September 30, 2014Assignees: GE Healthcare Limited, Hammersmith Imanet LimitedInventors: Irina Velikyan, Elisabeth Blom, Bengt Langstrom
-
Patent number: 8840951Abstract: The present invention relates to a method for the preparation of a controlled release system and especially to a method for entrapment of compounds in polymer carriers for controlled release of active ingredients, preferably bioactive ingredients, such as drugs. This method results in a system for controlled release of active ingredients and especially for controlled drug delivery. In accordance with the present invention, the tem controlled release” encompasses all kinds of controlled release, including slow release, sustained and delayed release. Particularly, the present invention results in active ingredients, entrapped in or otherwise incorporated in or coupled to polymer carriers or polymeric devices, such as micelles, nanoparticles, microspheres and other types of polymer devices for controlled release; the active ingredients are covalently bonded to the polymer carriers or polymeric devices.Type: GrantFiled: September 17, 2009Date of Patent: September 23, 2014Assignee: Cristal Delivery B.V.Inventors: Cristianne Johanna Ferdinand Rijcken, Wilhelmus Everhardus Hennink, Cornelis Franciscus Van Nostrum
-
Patent number: 8840865Abstract: Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecu le, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.Type: GrantFiled: September 30, 2013Date of Patent: September 23, 2014Assignee: Molecular Insight Pharmaceuticals, Inc.Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, John Marquis, Genliang Lu, Jian-cheng Wang, Shawn Hillier
-
Publication number: 20140271465Abstract: The present invention provides compound conjugates of matrix metalloprotease inhibitors and linked metal chelators which are useful for imaging solid tumors and treating and diagnosing certain types of diseases such as cancer.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Mallinckrodt LLCInventors: John N. Freskos, Mary Dyszlewski, Lori Chinen, Hector Knight, Michelle Schmidt
-
Publication number: 20140271466Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: G1 THERAPEUTICS, INC.Inventors: Norman E. Sharpless, Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
-
Patent number: 8834839Abstract: Imaging agents that comprise labeled substrates of the cystine/glutamate antiporter of cells, whereby the methods of use comprise introducing the labeled agents into cells via the cystine/glutamate antiporter, which are then reduced to a labeled cysteine, and subsequently detected in the cell.Type: GrantFiled: April 27, 2009Date of Patent: September 16, 2014Assignee: General Electric CompanyInventors: Paul Schaffer, Brian Duh-Lan Lee, Kande Kankanamalage Dayarathna Amarasinghe, Faisal Ahmed Syud, Rong Zhang, Jack Mathew Webster, Jennifer Lynne Huntington
-
Patent number: 8834841Abstract: The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. These compounds can also be labeled with technetium and rhenium isotopes using known chelation complexes. The compounds disclosed herein bind tumor tissues in vivo with high specificity and selectivity when administered to a subject. Preferred compounds show a target to non-target ratio of at least 2:1, are stable in vivo and substantially localized to target within 1 hour after administration. Preferred compounds include 1-amino-2-[18F]fluorocyclobutyl-1-carboxylic acid (2-[18F]FACBC) and 1-amino-2-[18]fluoromethylcyclobutyl-1-carboxylic acid (2-[18F]FMACBC).Type: GrantFiled: April 5, 2013Date of Patent: September 16, 2014Assignee: Emory UniversityInventor: Mark M. Goodman
-
Patent number: 8834840Abstract: Compositions and/or mixtures comprising peptide amphiphile compounds comprising one or more contrast agents, as can be used in a range of magnetic resonance imaging applications.Type: GrantFiled: October 4, 2007Date of Patent: September 16, 2014Assignee: Northwestern UniversityInventors: Steve R. Bull, Thomas J. Meade, Samuel I. Stupp
-
Patent number: 8834842Abstract: The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.Type: GrantFiled: March 11, 2013Date of Patent: September 16, 2014Assignee: Endocyte, Inc.Inventors: Christopher P. Leamon, Matthew A. Parker
-
Patent number: 8834843Abstract: The present invention relates to a method useful in facilitating the identification of fibrogenesis in a subject. The method of the invention is particularly useful when applied as part of a method to diagnose fibrogenesis of the liver. The invention also provides a compound for use in a method for identification of fibrogenesis in a subject A further aspect of the invention is a compound for use in the preparation of a medicament for use in a method for identification of fibrogenesis in a subject.Type: GrantFiled: November 19, 2008Date of Patent: September 16, 2014Assignee: GE Healthcare LimitedInventors: Ben Newton, Salah Chettibi, Magne Solbakken
-
Publication number: 20140255306Abstract: Compounds according to Formula I and Formula II are potent inhibitors of PSMA. Pharmaceutical compositions may include a complex of a radionuclide and a Formula I compound or a Formula II compound. Methods include using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.Type: ApplicationFiled: January 10, 2014Publication date: September 11, 2014Applicant: Molecular Insight Pharmaceuticals, Inc.Inventors: John W. BABICH, Craig ZIMMERMAN, John L. JOYAL, Genliang LU
-
Patent number: 8828355Abstract: Disclosed are compositions and methods for imaging in animals.Type: GrantFiled: September 16, 2005Date of Patent: September 9, 2014Assignee: University of Utah Research FoundationInventors: Charles Keller, Patrick J. Hawkes
-
Publication number: 20140248213Abstract: The present invention provides for heptamethine cyanine dyes that possess both nuclear and near-infrared imaging capabilities. These dyes can be used for imaging, targeting and detecting tumors in patients.Type: ApplicationFiled: October 5, 2012Publication date: September 4, 2014Applicants: CEDARS-SINAI MEDICAL CENTER, UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Leland W. K. Chung, Dongfeng Pan
-
Patent number: 8815213Abstract: RGD-chlorophyll and RGD-bacteriochlorophyll conjugates that home and accumulate in necrotic tumor domains much longer than in tumor non-necrotic domains are provided for use in minimally invasive tumor-targeted imaging, tumor-targeted photodynamic therapy, and/or on-line prognosis of necrotic tumors.Type: GrantFiled: March 1, 2009Date of Patent: August 26, 2014Assignee: Yeda Research and Development Co. Ltd.Inventors: Avigdor Scherz, Liat Goldshaid, Yoram Salomon
-
Publication number: 20140234216Abstract: The present invention is directed towards new trifunctional folate-conjugates comprising a folate, an albumin binder and a radionuclide-based therapeutic or diagnostic moiety as well as pharmaceutical compositions thereof, their method of production and their use in diagnostic and therapeutic medical applications, such as diagnostic nuclear imaging and radionuclide therapy.Type: ApplicationFiled: August 10, 2012Publication date: August 21, 2014Applicant: MERCK & CIEInventors: Roger Schibli, Rudolf Moser, Cristina Magdalena Muller, Harriet Struthers, Viola Groehn, Simon Mensah Ametamey, Cindy Ramona Fischer
-
Patent number: 8808665Abstract: The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for 18F imaging, while the therapeutic complex is of use for targeted delivery of chemotherapeutic drugs or toxins. More preferably, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment, using a click chemistry reaction involving cyclooctyne, nitrone or azide reactive moieties. In most preferred embodiments, the click chemistry reaction occurs in vivo. In vivo click chemistry is not limited to 18F labeling but can be used for delivering a variety of therapeutic and/or diagnostic agents.Type: GrantFiled: November 18, 2013Date of Patent: August 19, 2014Assignee: Immunomedics, Inc.Inventors: William J. McBride, Christopher A. D'Souza, David M. Goldenberg
-
Publication number: 20140219915Abstract: Disclosed herein is a method for coupling a first compound having the formula (I) with a second compound that contains a carbonyl group. Also disclosed herein are compounds that can be formed by this method, and uses for such compounds.Type: ApplicationFiled: July 6, 2012Publication date: August 7, 2014Applicants: AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION, THE AUSTRALIAN NATIONAL UNIVERSITYInventors: Suzanne Virginia Smith, Eskender Mume, Gary James Perkins
-
Patent number: 8790620Abstract: A composition including a radioactive fluorine-labeled amino acid compound is provided, which can be prevented from radiolysis. Disclosed is a composition which includes a solution containing a radioactive fluorine-labeled amino acid compound as an effective ingredient, in which the pH value of the solution is kept at 2.0-5.9, more preferably 2.0-4.9 in order to inhibit radiolysis. Also, it is possible to further inhibit radiolysis by adding thereto a pharmaceutical additive capable of inhibiting radiolysis, such as a sugar, a sugar alcohol and a sugar lactone, while the pH is kept at 2.0-5.9.Type: GrantFiled: November 20, 2007Date of Patent: July 29, 2014Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Akio Hayashi, Toshiyuki Shinmura, Daisaku Nakamura, Soichi Takasaki, Shinji Tokunaga, Emi Kaneko, Masahito Toyama
-
Publication number: 20140205537Abstract: Provided herein are compounds that inhibit or partially inhibit the activity of leucine rich repeat kinases. Also provided herein are methods of treatment of CNS disorders comprising administration of inhibitors of leucine rich repeat kinases.Type: ApplicationFiled: June 22, 2012Publication date: July 24, 2014Applicant: ZENOBIA THERAPEUTICS, INC.Inventors: Pierre-Yves Bounaud, Vicki Nienaber, Ruo W. Steensma, John A. Lowe, III
-
Patent number: 8785569Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.Type: GrantFiled: November 21, 2012Date of Patent: July 22, 2014Assignee: Original Biomedicals Co., Ltd.Inventors: Chau-Hui Wang, Chia-Hung Chen, Johnson Lin, Jing-Yi Chen, Wei-Chuan Liao
-
Publication number: 20140199239Abstract: The present disclosure provides lipid-probe compounds, and compositions comprising the compounds. A subject lipid-probe compound is useful for various imaging applications, which are also provided.Type: ApplicationFiled: May 16, 2011Publication date: July 17, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Carolyn Ruth Bertozzi, Andreas Stahl, Amy Helene Henkin, Elena A. Dubikovskaya, Allison Cohen
-
Patent number: 8778305Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.Type: GrantFiled: July 31, 2009Date of Patent: July 15, 2014Assignee: The Johns Hopkins UniversityInventors: Martin Pomper, Ronnie Charles Mease, Ying Chen
-
Patent number: 8778304Abstract: Translocator protein (TSPO) targeting compounds are described. Methods of making the compounds, and uses of the compounds for imaging are also described.Type: GrantFiled: February 24, 2011Date of Patent: July 15, 2014Assignee: The Johns Hopkins UniversityInventors: Martin G. Pomper, Haofan Wang, Tomas R. Guilarte
-
Patent number: 8778303Abstract: The invention encompasses radiopharmaceutical compounds that can be used in imaging cell death associated with either apoptosis or necrosis. Phosphatidylethanolamine (PtdE) is externalized to the surface of apoptotic cells, and also becomes accessible in necrotic cells due to compromised plasma membrane integrity. Duramycin, a 19 amino acid polypeptide, binds PtdE at a 1:1 ratio with high affinity and exclusive specificity. Novel Duramycin-based radiopharmaceuticals and non-radioactively labeled compounds are disclosed herein. Such compounds facilitate detection of cell apoptosis and/or necrosis by binding to PtdE. The location of the bound compound can then be pinpointed using standard imaging techniques.Type: GrantFiled: January 10, 2011Date of Patent: July 15, 2014Assignee: The Medical College of Wisconsin, Inc.Inventor: Ming Zhao
-
Patent number: 8778310Abstract: A chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues, compositions that include the chlorotoxin conjugate, and methods for using the chlorotoxin conjugate.Type: GrantFiled: August 31, 2007Date of Patent: July 15, 2014Assignees: University of Washington, Fred Hutchinson Cancer Research CenterInventors: Miqin Zhang, Richard G. Ellenbogen, Raymond W. Sze, Omid Veiseh, James M. Olson, Mandana Veiseh, Patrik Gabikian, S-Bahram Bahrami
-
Patent number: 8778300Abstract: A method of forming an injectable radioactive composition, the method comprising the steps of: (a) depositing a solid form of technetium onto a carbon crucible; (b) preheating the solid form of technetium to remove any carrier; (c) plasma ablating the technetium and portions of the carbon crucible; (d) allowing the carbon and technetium metal to co-condense from the gas phase to produce a nanoparticle composite aerosol in an inert gas; (e) dispersing the nanoparticle composite in water containing a low concentration of surfactant using an electrostatic precipitator; (f) size fractionating the nanoparticle dispersion by filtration with hydrophilic membranes of known pore size.Type: GrantFiled: April 28, 2006Date of Patent: July 15, 2014Assignee: The Australian National UniversityInventors: William Martin Burch, Timothy John Senden, Ross Wentworth Stephens, Beverley Ann Browitt
-
Patent number: 8778302Abstract: The invention provides compositions and method for delivering a therapeutic or diagnostic agent to a disease site in a mammal, the method comprising administering to the mammal a therapeutically or diagnostically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises the therapeutic or diagnostic agent coupled to a Procaspase 8 polypeptide and a pharmaceutically acceptable carrier.Type: GrantFiled: March 7, 2008Date of Patent: July 15, 2014Assignee: The University of British ColumbiaInventor: Isabella Tai
-
Publication number: 20140193336Abstract: Protocols for radioimaging an event or disorder are provided. An exemplary protocol comprises a method of radioimaging a myocardial perfusion, the method comprising in sequence: (a) administering to a subject about 3 mCi Tl201 thallous chloride; (b) allowing said subject to rest; (c) radioimaging a heart of said subject; (d) subjecting said subject to a physical stress; (e) administering to said subject at a peak of said physical stress about 20-30 mCi Tc99m sestamibi; and (f) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.Type: ApplicationFiled: January 6, 2014Publication date: July 10, 2014Applicant: Biosensors International Group, Ltd.Inventors: Benny ROUSSO, Dalia Dickman, Yael Nir, Michael Nagler, Zohar Bronshtine, Shankar Vallabhajosula, Shlomo Ben-Haim, Simona Ben-Haim
-
Patent number: 8771645Abstract: The invention relates to the use of a cell death marker labelled with a wavelength-optimised label for identifying cell death in the eye. Suitable cell death markers are the Annexins and fragments and derivatives thereof. The invention also relates to a pharmaceutical composition comprising a cell death marker labelled with a wavelength-optimised label and a method for monitoring cell death in the eye using a cell death marker labelled with a wavelength-optimised label.Type: GrantFiled: December 15, 2008Date of Patent: July 8, 2014Assignee: UCL Business PLLCInventors: Francesca Cordeiro, Stephen Moss, Frederick Fitzke
-
Publication number: 20140186260Abstract: A radiopharmaceutical comprising combination of a particular radioactive dithiosemicarbazone copper complex, and a chelating agent comprising a multidentate ligand having a maximum dentate number of 2 or more to 4 or less.Type: ApplicationFiled: December 24, 2013Publication date: July 3, 2014Applicants: NIHON MEDI-PHYSICS CO., LTD., NATIONAL CANCER CENTER, NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCESInventors: Yukie YOSHII, Hiroki Matsumoto, Mitsuyoshi Yoshimoto